TARGET AUDIENCE: This conference will be of particular interest and value to the faculty, staff, and students of the College of Public Health and the Health Science Colleges.

ABSTRACT:
Sulfonylureas remain important in the armamentarium of clinicians treating type 2 diabetes mellitus. Agents within this drug class are at least initially effective, generally well tolerated, and inexpensive. Yet, there are major concerns for serious hypoglycemia and untoward cardiovascular effects. To help inform second-line antidiabetic therapy prescribing decisions, it is critical to understand the safety of individual sulfonylureas. This talk will examine Dr. Leonard’s pharmacoepidemiologic studies elucidating adverse effects of sulfonylureas, including investigations of: a) serious hypoglycemia potentiated by drug interactions; and b) sudden cardiac arrest.

DISCLOSURE STATEMENT: “I do not have any financial interests or other relationships with any manufacturers of products or providers of services I might be discussing in my presentation.”

Charles E. Leonard, PharmD, MSCE
Research Assistant Professor
Department of Biostatistics, Epidemiology, and Informatics
Perelman School of Medicine
University of Pennsylvania

Thursday, March 8th, 2018
11:30 am – 12:20 pm
Ellig Classroom (N120 CPHB)